Biomarker analysis in a phase III study of pemetrexed-carboplatin versus etoposide-carboplatin in chemonaive patients with extensive-stage small-cell lung cancer. [electronic resource]
Producer: 20121022Description: 1723-9 p. digitalISSN:- 1569-8041
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Biomarkers, Tumor -- genetics
- Carboplatin -- administration & dosage
- Clinical Trials, Phase III as Topic
- Collagen Type XVIII -- genetics
- DNA-Binding Proteins -- metabolism
- Disease-Free Survival
- Endonucleases -- metabolism
- Etoposide -- administration & dosage
- Glutamates -- administration & dosage
- Guanine -- administration & dosage
- Humans
- Kaplan-Meier Estimate
- Logistic Models
- Lung Neoplasms -- drug therapy
- Methylenetetrahydrofolate Reductase (NADPH2) -- genetics
- Pemetrexed
- Peptide Synthases -- genetics
- Phosphoribosylglycinamide Formyltransferase -- metabolism
- Polymorphism, Single Nucleotide
- Randomized Controlled Trials as Topic
- Reduced Folate Carrier Protein -- genetics
- Small Cell Lung Carcinoma -- drug therapy
- Thymidylate Synthase -- metabolism
No physical items for this record
Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.